Skip to main content
OpenTrials
Completed

NCT Number: NCT00880646

Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity

This study aims to investigate the effect of supplement containing L-arabinose and indigestible dextrin on body mass index, body fat mass, abdominal circumference, visceral fat mass, and serum biochemical parameters in overweight subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Obesity Body Weight Nutrition Disorders Nutritional and Metabolic Diseases Overnutrition Overweight Pathological Conditions, Signs and Symptoms Signs and Symptoms

Age range

20 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hiroshima University

Hiroshima, 734-8551, Japan

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy as based on medical history and physical examination
  • BMI between 25 and 30 kg/m2
  • Willing not to serve as blood donor during the study
  • Informed consent signed

Exclusion criteria

  • Female subjects who are pregnant or nursing a child
  • Participation in any clinical trial up to 90 days before Day 01 of this study
  • Renal or hepatic dysfunction
  • Heart disease
  • Under medication
  • Subjects who are taking functional food designed for weight loss or serum lipid reduction

Treatment and study plan

Oolong tea containing L-arabinose and indigestible dextrin

Dietary Supplement

Oolong tea (Placebo)

Dietary Supplement

Primary outcomes

  1. Body mass index

    Time frame: 20 weeks

Secondary outcomes

  1. Body fat mass

    Time frame: Every 4 weeks (Overall 20 weeks)

  2. Abdominal circumference

    Time frame: Every 4 weeks (Overall 20 weeks)

  3. Visceral fat area by CT scan

    Time frame: Week 0, Week 12

  4. Serum lipid profile

    Time frame: Every 4 weeks (Overall 20 weeks)

  5. Serum adiponectin and leptin levels

    Time frame: Week 0, Week 12

  6. Fasting serum glucose and HbA1c levels

    Time frame: Every 4 weeks (Overall 20 weeks)

  7. Frequency of bowel movement

    Time frame: 20 weeks

Interested in participating?

Completed

Looking for future studies?

Notify Me

Sponsors and collaborators

Lead sponsor

Hiroshima University

Other

Collaborators

  • Unitika Ltd.

Registry information

Official study title

Effects of the Combination of L-Arabinose and Indigestible Dextrin on Obesity: a Double-Blind, Randomized Controlled Trial

Important dates

Study start
2009
Study completion
2009
First posted
Apr 14, 2009
Registry last updated
Oct 29, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.